Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

23 December 2025

Envafolimab Was Granted Another Orphan Drug Designation by the U.S. FDA for the Treatment of GC/GEJ This marks the third ODD awarded to Envafolimab, following previous designations for advanced biliary tract cancer and soft tissue sarcoma
22 December 2025

Alphamab Oncology Announces Bispecific ADC JSKN016 in Combination with InventisBio's D-0502 Approved for Clinical Trial in Breast Cancer Treatment for the treatment of locally advanced or metastatic HR-positive, HER2-negative (HR+/HER2-) breast cancer
20 December 2025

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC The grant of this BTD further demonstrates the international regulatory community’s recognition of JSKN003’s clinical potential and its importance as a novel therapeutic candidate
18 December 2025

Alphamab Oncology Announces IND Application for Innovative PD-L1/VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE The Company plans to initiate a clinical study of JSKN027 for the treatment of advanced malignant solid tumors
09 December 2025

Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held The event focused on the latest advancements in the field of ADCs, comprehensively showcasing the company's R&D achievements in bispecific ADCs and dual-payload ADCs.
25 November 2025

Alphamab Oncology Retains Prestigious Industry Awards, Sustaining Leading Innovative Strength highlighting the company's comprehensive strength and leading position in the field of Chinese biological innovative drugs
06 November 2025

Alphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego The modularly designed dual-payload ADC platform technology and the prominent preclinical efficacy of JSKN021 garnered attention from attendees, making it one of the most remarkable highlights of Chin...
28 October 2025

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC As a significant milestone in its global development progress, this achievement fully validates the drug's substantial clinical potential and market prospects
27 October 2025

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer This marks the fourth Phase III clinical study initiated for JSKN003
24 October 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022 JSKN022 is the Company’s fourth ADC candidate entering clinical development, as well as the world's first PD-L1/αvβ6 bispecific ADC to advance into clinical trials